CA Ⅱ
Carbonic Anhydrase II (CA II) is a cytosolic zinc metalloenzyme that catalyzes the reversible hydration of carbon dioxide to bicarbonate and a proton, a reaction central to acid-base homeostasis, carbon dioxide transport, and cellular pH regulation[1][2]. CA II is the best-characterized human carbonic anhydrase isoform and exhibits exceptionally high catalytic efficiency, making it a key regulator of bicarbonate-dependent physiological processes in erythrocytes, kidney, bone, eye, and other tissues[2][3]. Mechanistically, CA II supports bicarbonate transport and acidification pathways that are required for renal bicarbonate reabsorption and osteoclast-mediated bone resorption[1][4]. In disease settings, inherited CA II deficiency causes the autosomal recessive syndrome characterized by osteopetrosis, renal tubular acidosis, and cerebral calcification, providing direct genetic evidence for the essential role of this isoform in bone and renal physiology[4][5]. Compared with related carbonic anhydrase isoforms, CA II is distinguished by its broad tissue distribution, dominant catalytic activity, and well-established involvement in bicarbonate transport metabolons and vascular regulatory processes[3][6]. These characteristics have made CA II one of the most extensively studied experimental models for enzyme catalysis, structure-guided drug discovery, and inhibitor development[3][7]. Sulfonamide-based carbonic anhydrase inhibitors, including clinically used agents, bind the catalytic zinc center and have been widely employed to investigate CA II function and therapeutic modulation in disorders such as glaucoma and other bicarbonate-dependent pathologies[6][7].
References:
- [1]. Sly WS, et al. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A. 1983 May;80(9):2752-6. [Content Brief]
- [2]. Roy BC, et al. Two-prong inhibitors for human carbonic anhydrase II. J Am Chem Soc. 2004 Oct 20;126(41):13206-7. [Content Brief]
-
CA Ⅱ Related Products (119)
Related Products (119)
-
Recombinant Proteins (3)
-
CA/HDAC-IN-1
0 ImagesCat. No.: HY-179271CA/HDAC-IN-1 (Compound 11) is a CA and HDAC inhibitor with Ki values of 7.4 nM, 31.0 nM, and 7.3 nM for hCA II, hCA IX, and hCA XII, respectively, and IC50 values of 0.21 μM and 3.60 μM for HDAC3 and HDAC8, respectively. CA/HDAC-IN-1 has anti-cancer activity against colon cancer, breast cancer, and melanoma.
-
Carbonic anhydrase-IN-35
0 ImagesCat. No.: HY-175638Carbonic anhydrase-IN-35 is a selective carbonic anhydrase (CA) inhibitor. Carbonic anhydrase-IN-35 potently inhibits tumor-associated hCA IX (Ki = 0.6 nM) and hCA XII (Ki = 2.2 nM). Carbonic anhydrase-IN-35 induces apoptosis in MCF-7 cells by elevating Bax, reducing Bcl-2, and downregulating CDK4/6. Carbonic anhydrase-IN-35 exhibits potent cytotoxicity against MCF-7 (IC50 = 0.3975 μM normoxic/0.6575 μM hypoxic), MCF-7-ADR (IC50> = 0.3975 μM normoxic/4.488 μM hypoxic), MDA-MB-231, and 4T1 breast cancer cells. Carbonic anhydrase-IN-35 can be used for the study of breast cancer.
-
hCAIX-IN-21
0 ImagesCat. No.: HY-159128CAS No.: 3047757-55-8hCAIX-IN-21 (compound 16c) is a potent hCAIX inhibitor with KI values of 5.2, 3.5, 12.6, 13600 nM for hCAIX, hCA II, hCA XII, hCA I, respectively. hCAIX-IN-21 inhibits cathepsin B enzyme activity.
-
Methazolamide-d6
0 ImagesCat. No.: HY-B0553SCAS No.: 1795142-30-1Synonyms: L584601-d6Methazolamide-d6 is the deuterium labeled Methazolamide. Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders.
-
STAT3/CAIX-IN-1
0 ImagesCat. No.: HY-174457CAS No.: 3053583-60-8STAT3/CAIX-IN-1 is a dual-target inhibitor of STAT3 (Kd: 60.03 μM) and CAIX (IC50: 80.45 nM). STAT3/CAIX-IN-1 induces ferroptosis by increases the levels of reactive oxygen species (ROS) and lipid peroxides. STAT3/CAIX-IN-1 inhibits cell migration, induces apoptosis, and causes cell cycle arrest in MDA-MB-231 cells. STAT3/CAIX-IN-1 can be used for the study of triple-negative breast cancer (TNBC).
-
CAII-IN-11
0 ImagesCat. No.: HY-180916CAII-IN-11 (Compound A1) is a dual-target compound that contains a hCA II inhibitor (IC₅₀ = 2 nM) portion and a NO donor portion. CAII-IN-11 also has inhibitory activity against hCA IX, hCA XII, and hCA I, with IC50 values of 6, 3, and 152 nM respectively. CAII-IN-11 significantly increases the intracellular cGMP level in human trabecular meshwork cells. CAII-IN-11 reduces the apoptosis of retinal ganglion cells by reducing oxidative stress (ROS levels), inhibiting astrocytes and the NLRP3 inflammasome activation. CAII-IN-11 has hypotensive activity in rabbit models and can be used for the study of glaucoma.
-
CA IX/VEGFR-2-IN-3
0 ImagesCat. No.: HY-170551CA IX/VEGFR-2-IN-3 (Compound 6i) is an inhibitor of Carbonic Anhydrase IX and VEGFR-2, with IC50 values of 41 and 48 nM, respectively. CA IX/VEGFR-2-IN-3 exhibits anticancer activity, inhibiting the growth of MCF-7 breast cancer cells (with an IC50 of 22.33 μM) and mouse fibroblast cell line 3T3 (where cell viability is less than 40% at a concentration of 100 μM). CA IX/VEGFR-2-IN-3 can be used for research in the field of cancer treatment.
-
hCAII-IN-3
0 ImagesCat. No.: HY-146008CAS No.: 2770927-76-7hCAII-IN-3 (Compound 16) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 403.8, 5.1, 10.2 and 5.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-2 shows anticancer activity.
-
CAI/II-IN-8
0 ImagesCat. No.: HY-161507CAS No.: 3036136-18-9CAI/II-IN-8 (Compound 8) is a hydrazide derivative based on 4-hydroxybenzaldehyde. CAI/II-IN-8 primarily targets human carbonic anhydrase isomerase I (hCA I) and II (hCA II) for inhibition (IC50 = 21.35 ± 0.39 nM (CA I); 7.12 ± 0.12 nM (CA II)). CAI/II-IN-8 inhibits AChE and BChE as well(IC50 = 46.27 ±0.75 nM (AChE); 43.38 ± 0.83 nM (BChE)). ..
-
hCAIX/XII-IN-15
0 ImagesCat. No.: HY-173394CAS No.: 69141-46-4hCAIX/XII-IN-15 (Compound 17β) is an inhibitor of hCA IX and hCA XII, with Kis of 0.42 and 4.37 μM respectively. hCAIX/XII-IN-15 has pro-apoptotic effect in multiple myeloma cells.
-
hCA-I/hCA-II-IN-1
0 ImagesCat. No.: HY-174835hCA-I/hCA-II-IN-1 (Compound P4) is a potent dual human carbonic anhydrase I (hCA-I) and human carbonic anhydrase II (hCA-II) inhibitor with Ki values of 0.22 μM and 0.33 μM, respectively. hCA-I/hCA-II-IN-1 can be used in research on diseases related to CA enzymes such as glaucoma, hypertension, and ulcers.
-
CA-II/Dkk1-IN-1
0 ImagesCat. No.: HY-175219CA-II/Dkk1-IN-1 (Compound 5d) is a dual-functional inhibitor of CA-II and Dkk1 with a IC50 of 6.90 nM for CA-II. CA-II/Dkk1-IN-1 has significantly antioxidant activity and superior DNA binding capacity. CA-II/Dkk1-IN-1 can be used for cancers research, such as esophageal, renal, and lung cancer.
-
hCAIX/XII-IN-9
0 ImagesCat. No.: HY-162063hCAIX/XII-IN-9 (compound 8) is a potent carbonic anhydrase (CA) inhibitor with Ki values of 1658 nM, 184.8 nM, 8.9 nM, 64.8 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively.
-
ALP/Carbonic anhydrase-IN-1
0 ImagesALP/Carbonic anhydrase-IN-1 (Compound 1e) is a dual carbonic anhydrase (CA) and alkaline phosphatase (ALP) inhibitor. ALP/Carbonic anhydrase-IN-1 shows IC50 values of 0.44 µM, 1.61 µM, 0.51 µM, and 0.107 µM for CA-II, CA-IX, CA-XII, and ALP, respectively.
-
CAI/II-IN-4
0 ImagesCat. No.: HY-147925CAS No.: 2480284-01-1CAI/II-IN-4 (compound 6d) is a potent dual hCA I/II inhibitor with Ki values of 16.95, 15.22 and 27.04 nM for hCA I, hCA II and hCA Ⅸ, respectively. CAI/II-IN-4 has anti-hypoxia activities and low toxicity. CAI/II-IN-4 can be used for acute mountain sickness (AMS) research.
-
CAI/II-IN-1
0 ImagesCat. No.: HY-146385CAS No.: 2422028-82-6CAI/II-IN-1 (Compound 3h) is a human carbonic anhydrase I and II (hCA I/II) inhibitor with IC50 values of 0.047 µM and 0.024 µM against hCA I and hCA II, respectively.
-
HCAIX-IN-1
0 ImagesCat. No.: HY-146206CAS No.: 2389034-65-3HCAIX-IN-1 is a selective HCAIX inhibitor with a Ki value of 3.3 nM for hCA IX. HCAIX-IN-1 can be used in the study of solid tumors.
-
Dorzolamide hydrochloride (Standard)
0 ImagesSynonyms: L671152 hydrochloride(Standard); MK507 hydrochloride (Standard)Dorzolamide (hydrochloride) (Standard) is the analytical standard of Dorzolamide (hydrochloride). This product is intended for research and analytical applications. Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
-
Carbonic anhydrase inhibitor 20
0 ImagesCat. No.: HY-161374CAS No.: 3034045-43-4Carbonic anhydrase inhibitor 20 (compound 11) is an inhibitor of piperazinosulfonamide carbonic anhydrase (Carbonic Anhydrase). The Ki of Carbonic anhydrase inhibitor 20 for hCA I, hCA II, hCA IX, and hCA XII are 47.6 nM, 36.5 nM, 8.3 nM, and 2.7 nM respectively.
